News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Here's Why The Best Is Yet To Come for Exelixis (EXEL)



4/21/2017 6:07:40 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Exelixis (NASDAQ:EXEL) has been on a tear over the last year, nearly quadrupling.

While much of the growth in Exelixis' stock price has to do with the better-than-expected launch of Cabometyx in kidney cancer, the biotech still has room to run.

Read at Motley Fool


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES